AZD8186, a selective competitive ATP inhibitor against PI3Kβ and PI3Kδ, has been shown to effectively suppress tumor growth in the PTEN-deficient cancer cell lines (MDA-MB-436 and MDA-MB-468)-derived xenografts, particularly when combined with paclitaxel [147,151]. Here, PTEN is linked to neoplasm.